Instructions Calcium chloride solution for injection 10% 10ml No. 10
Composition
active ingredient: 1 ml of solution contains calcium chloride 100 mg;
excipient: water for injections.
Dosage form
Solution for injection.
Main physicochemical properties: clear colorless liquid.
Pharmacotherapeutic group
Blood substitutes and perfusion solutions. Electrolyte solutions. ATX code B05X A07.
Pharmacological properties
Pharmacodynamics.
The drug eliminates the deficiency of calcium ions. Calcium ions are involved in the transmission of nerve impulses, contraction of smooth and skeletal muscles, in the functional activity of the myocardium, blood clotting; necessary for the formation of bone tissue, the functioning of other systems and organs. The concentration of calcium ions in the blood decreases as a result of many pathological processes, severe hypocalcemia contributes to the appearance of tetany. Calcium chloride, in addition to eliminating hypocalcemia, reduces vascular permeability, and exhibits a hemostatic effect.
Pharmacokinetics.
In the blood, calcium is in compounds and in an ionized state. Physiological activity is inherent in ionized calcium. It is deposited in bone tissue. It is excreted from the body with urine, but mainly with feces.
Indication
Cases of hypocalcemia requiring a rapid increase in the concentration of calcium ions in the blood plasma (tetany in functional insufficiency of the parathyroid gland, tetany in vitamin D deficiency, hypocalcemia in exchange transfusion and infusion of citrated blood, alkalosis). As part of complex therapy for acute lead colic. Cases of magnesium intoxication occurring with magnesium overdose. Hyperkalemia registered on the ECG with impaired cardiac function.
Contraindication
Hypersensitivity to the components of the drug. Hypercalcemia, severe hypercalciuria, nephrourolithiasis (calcium), severe renal failure, sarcoidosis, hypercoagulation. Atherosclerosis with arterial occlusion phenomena. Tendency to thrombosis. Ventricular fibrillation. Asystole and electromechanical dissociations. Taking digitalis preparations. Simultaneous use with ceftriaxone.
Interaction with other medicinal products and other types of interactions
Do not use with thiazide diuretics or vitamin D due to increased risk of hypercalcemia. Calcium chloride and ceftriaxone should not be administered simultaneously. In patients of any age, ceftriaxone should not be mixed or administered simultaneously with calcium-containing infusion solutions, even through different infusion systems or at different injection sites. However, patients may receive ceftriaxone and calcium-containing solutions sequentially if the infusion sites are different or if the infusion system is replaced or thoroughly flushed with saline to avoid precipitation.
Calcium-containing products can reduce the effectiveness of calcium channel blockers, reduce the effect of calcitonin in hypercalcemia, and the bioavailability of phenytoin. Calcium chloride reduces the cardiotonic effects of dobutamine. Calcium salts reduce the absorption of drugs such as bisphosphonates, fluorides, and some fluoroquinolones. When used simultaneously, it reduces the effect of calcium channel blockers; with quinidine, a slowdown in intraventricular conduction and increased quinidine toxicity are possible. During treatment with cardiac glycosides, parenteral administration of calcium chloride is not recommended due to increased cardiotoxic effects.
Concomitant administration with other calcium- or magnesium-containing drugs increases the risk of hypercalcemia or hypermagnesemia, respectively, especially in patients with chronic renal failure.
The drug reduces the effectiveness of non-polarizing muscle relaxants. May increase the duration of action of tubocurarine chloride.
Application features
With prolonged use in high doses, hypercalcemia with deposition of calcium salts in the body is possible.
The injection should be made through a thin needle into a large vein to minimize the damaging effect of the drug on the vascular wall. The solution should be warmed to body temperature. Calcium chloride should not be administered subcutaneously or intramuscularly due to its strong irritating and necrotizing effect. If the drug solution gets under the skin or into the muscle, it should be removed as much as possible with a syringe and 10 ml of sodium sulfate, 25% solution for injection, or 5-10 ml of magnesium sulfate, 25% solution for injection, should be injected into the injection site. To eliminate the resorptive effect, prescribe diphenhydramine, and in case of hypercalcemia - EDTA.
When using it, it is necessary to carefully monitor the level of calcium in the blood. It should be used with caution in patients with kidney disease, dehydration, electrolyte imbalance (risk of hypercalcemia), heart disease (risk of arrhythmia), nephrolithiasis or diseases accompanied by hypercalcemia (including malignant neoplasms and sarcoidosis), "pulmonary" heart, respiratory acidosis, respiratory failure (risk of toxic reactions due to oxidation of calcium chloride). When using it, it is necessary to carefully monitor the level of calcium in the blood. Calcium chloride for injection should not be administered orally to children due to possible severe irritation of the gastrointestinal tract.
Children should not have the drug injected into the veins on their heads.
Use during pregnancy or breastfeeding
Use during pregnancy is possible only if the benefit to the mother outweighs the potential risk to the fetus.
The drug can be used during breastfeeding.
Ability to influence reaction speed when driving vehicles or other mechanisms
During treatment with the drug, driving and working with dangerous mechanisms are contraindicated.
Method of administration and doses
Calcium chloride should be administered intravenously by jet (very slowly) and intravenously by drip (slowly).
Adults.
Intravenous injection: 5 ml of 10% solution administered at a rate of 1 ml/min. Intravenous injection: 5-10 ml of 10% solution of the drug diluted in 100-200 ml of 0.9% sodium chloride solution or 5% glucose solution; administered at a rate of 6-8 drops/min.
Exchange transfusion and citrate blood transfusion: adults and children 30 mg (0.3 ml) for every 100 ml of blood.
Hypocalcemia: 500 mg to 1 g (5-10 ml) at intervals of 1 to 3 days, depending on the patient's response or plasma calcium level. If necessary, a second dose may be administered.
Magnesium intoxication: 500 mg (5 ml) administered rapidly. The patient should be monitored until recovery before further doses are administered.
Hyperkalemia, registered on the ECG with impaired cardiac function: the dose should be selected individually, depending on the patient's condition under constant cardiogram monitoring.
Tetany in adults: 10 ml of a 10% solution (1 g) over 10-30 minutes, if necessary, repeat the administration after 6 hours.
For children.
Hypocalcemia: administer slowly, at a rate of up to 0.5 ml/min, at a dose of 10-20 mg/kg body weight (0.1-0.2 ml/kg body weight), repeat every 4-6 hours if necessary.
Tetany: 10 mg/kg body weight (0.1 ml/kg body weight) over 5-10 minutes, if necessary repeat the administration after 6 hours or continue as an infusion. The maximum daily dose for children (regardless of age) is 10 ml (1000 mg).
Doses for elderly patients are the same as those for adults.
Children. Use in children is possible from 1 year of age.
Overdose
Overdose can cause depression of cardiac activity, tachycardia and a sharp decrease in blood pressure, as well as acute hypercalcemic syndrome: anorexia, nausea, vomiting, constipation, abdominal pain; mental disorders, drowsiness, muscle weakness, arthralgia, polyuria, polydipsia, nephrolithiasis, in severe cases - cardiac arrhythmias, coma.
Treatment: Stop administration of the drug. Symptomatic therapy.
Side effects
Hypersensitivity reactions: a feeling of heat first in the mouth and then throughout the body; facial flushing;
Cardiovascular system: moderate and short-term decrease in blood pressure; bradycardia, arrhythmia, arterial hypertension, venous thrombosis; rapid intravenous administration may cause dilation of blood vessels, ventricular fibrillation;
Skin and subcutaneous tissue disorders: soft tissue calcification;
general disorders: chalky taste, hypercalcemia;
local reactions: tissue necrosis, pain and hyperemia at the injection site.
Expiration date
5 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25°C.
Keep out of reach of children.
Incompatibility
Calcium chloride should not be mixed with carbonates, phosphates, sulfates, tartrates, and tetracycline antibiotics in parenteral formulations. Calcium chloride should not be mixed in the same injection with ceftriaxone because of the possibility of precipitation.
Packaging
5 ml or 10 ml in an ampoule; 5 ampoules in a contour blister pack; 2 contour blister packs in a pack.
Vacation category
According to the recipe.
Producer
PJSC "Galychpharm".
Address
Ukraine, 79024, Lviv, Opryshkivska St., 6/8.
